Condition: Platinum-resistant Ovarian Cancer · Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Sponsor: MacroGenics
Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.
This description comes directly from the study's public registry record.
Global Trial Manager · 301-251-5172 · info@macrogenics.com
Always discuss trial participation with your own doctor first.
| UCLA | Los Angeles, California, United States | Recruiting |
| Ochsner MD Anderson Cancer Center | New Orleans, Louisiana, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| West Penn Allegheny Health | Pittsburgh, Pennsylvania, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center, Gynecologic Oncology Center | Houston, Texas, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| Wisconsin Institute Medical Research- UW Cancer Connect | Madison, Wisconsin, United States | Recruiting |
| Princess Margaret Cancer Center | Toronto, Ontario, Canada | Recruiting |
| McGill University | Montreal, Quebec, Canada | Recruiting |
| National Cancer Center | Goyang-si, Gyeonggi-do, South Korea | Recruiting |
| Seoul National University Hospital Bundang Hospital | Seongnam-si, Gyeonnggi-Do, South Korea | Recruiting |
| Yonsei University Health System Severance Hospital | Seoul, South Korea | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06730347